Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton vs photon chemoradiotherapy followed by immunotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2600130715Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of toripalimab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Overall survival (OS). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
toripalimabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600130715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130715.